Neumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Neumora Therapeutics

14/08/2026 13:20

Neumora Therapeutics Inc NMRA.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -33 cents.  The mean expectation of nine analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -30 cents to -20 cents per share.
Reported revenue was zero​; analysts expected zero. 
Neumora Therapeutics Inc's reported EPS for the quarter was a loss of 23 cents​.
The company reported a quarterly loss of $43.08 million.
Neumora Therapeutics Inc shares had risen by 1.8% this quarter and lost 3.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Neumora Therapeutics Inc is $5.00, about 65.4% above its last closing price of $1.73
This summary was machine generated from LSEG data August 14 at 12:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.24
-0.23
Beat
Mar. 31 2026 
-0.31
-0.30
Beat
Dec. 31 2025 
-0.33
-0.35
Missed
Sep. 30 2025 
-0.33
-0.32
Beat